Pharmacist surveillance of adverse drug events
- PMID: 15332694
- DOI: 10.1093/ajhp/61.14.1466
Pharmacist surveillance of adverse drug events
Abstract
Purpose: The incidence of adverse drug events (ADEs), preventable ADEs, and potential ADEs was determined using pharmacist surveillance. Drug classes associated with ADEs were also identified.
Methods: The study was conducted in a 30-bed hospital ward of a Canadian teaching hospital between April 28, 2003, and May 26, 2003. All patients admitted to the general medicine service were eligible for study enrollment. A pharmacist performed surveillance to identify new or worsening symptoms, critical laboratory values, and medication errors. Surveillance consisted of daily communications with staff, daily chart reviews for all inpatients, and investigation of spontaneous incident reports. Data were collected to describe all identified outcomes. This information was rated independently by two clinicians to determine if the outcome was an ADE, a preventable ADE, or a potential ADE. Descriptive statistics were used to calculate outcome rates, which were reported as events per 100 patient-days.
Results: During 543 patient-days of observation, 24 ADEs occurred (4.4 per 100 patient-days), of which 14 were preventable (2.6 per 100 patient-days); 13 potential ADEs also occurred (2.4 per 100 patient-days). Of all ADEs, 3 (13%) were life threatening, 11 (46%) were serious, and 10 (42%) were significant. The 24 ADEs were associated with nine different drug classes. Four drug classes accounted for 17 ADEs (71%): antidiabetic agents, antibiotics, glucocorticoids, and sedatives and hypnotics.
Conclusion: Pharmacist surveillance revealed that 4.4 ADEs occurred per 100 patient-days, over half of which were preventable. All preventable and potential ADEs occurred during the ordering and administration stages of medication delivery.
Similar articles
-
Incidence, preventability, and impact of Adverse Drug Events (ADEs) and potential ADEs in hospitalized children in New Zealand: a prospective observational cohort study.Paediatr Drugs. 2009;11(2):153-60. doi: 10.2165/00148581-200911020-00005. Paediatr Drugs. 2009. PMID: 19301935
-
Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group.JAMA. 1995 Jul 5;274(1):29-34. JAMA. 1995. PMID: 7791255
-
Incidence of adverse drug events in an academic hospital: a prospective cohort study.Int J Qual Health Care. 2013 Dec;25(6):648-55. doi: 10.1093/intqhc/mzt075. Epub 2013 Oct 17. Int J Qual Health Care. 2013. PMID: 24141014
-
Adverse drug events and medication errors in Australia.Int J Qual Health Care. 2003 Dec;15 Suppl 1:i49-59. doi: 10.1093/intqhc/mzg085. Int J Qual Health Care. 2003. PMID: 14660523 Review.
-
Comprehensive Literature Review of Factors Influencing Medication Safety in Nursing Homes: Using a Systems Model.J Am Med Dir Assoc. 2017 Jun 1;18(6):470-488. doi: 10.1016/j.jamda.2016.12.069. Epub 2017 Feb 24. J Am Med Dir Assoc. 2017. PMID: 28242191 Review.
Cited by
-
Improving patient safety through the systematic evaluation of patient outcomes.Can J Surg. 2012 Dec;55(6):418-25. doi: 10.1503/cjs.007811. Can J Surg. 2012. PMID: 23177520 Free PMC article. Review.
-
A comparison of active surveillance programs including a spontaneous reporting model for phamacovigilance of adverse drug events in a hospital.Korean J Intern Med. 2012 Dec;27(4):443-50. doi: 10.3904/kjim.2012.27.4.443. Epub 2012 Nov 27. Korean J Intern Med. 2012. PMID: 23269886 Free PMC article.
-
Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal.Drug Saf. 2008;31(4):335-44. doi: 10.2165/00002018-200831040-00007. Drug Saf. 2008. PMID: 18366244 Clinical Trial.
-
Validation of a discharge summary term search method to detect adverse events.J Am Med Inform Assoc. 2005 Mar-Apr;12(2):200-6. doi: 10.1197/jamia.M1653. Epub 2004 Nov 23. J Am Med Inform Assoc. 2005. PMID: 15561788 Free PMC article.
-
Methods for assessing the preventability of adverse drug events: a systematic review.Drug Saf. 2012 Feb 1;35(2):105-26. doi: 10.2165/11596570-000000000-00000. Drug Saf. 2012. PMID: 22201475
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous